2026-08-05T09:54:34Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/168372025-04-01T09:07:07Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Fontán-Vela, Mario author Hernando Sebastian, Victoria author Olmedo, Carmen author Coma, Ermengol author Martínez, Montse author Moreno-Perez, David author Lorusso, Nicola author Vázquez Torres, María author Barbas del Buey, José Francisco author Roig-Sena, Javier author Pastor, Eliseo author Galmés Truyols, Antònia author Artigues Serra, Francisca author Sancho Martínez, Rosa María author Latasa Zamalloa, Pello author Pérez Martínez, Olaia author Vázquez Estepa, Ana author García Rojas, Amós José author Barreno Estévez, Ana Isabel author Sánchez-Migallón Naranjo, Alonso author Pérez Martín, Jaime Jesús author Peces Jiménez, Pilar author Morales Romero, Raquel author Castilla, Jesús author Garcia-Cenoz, Manuel author Huerta Huerta, Marta author Boone, An Lieve Dirk author Macías Ortiz, María José author Álvarez Río, Virginia author Rodríguez Recio, María Jesús author Merino Díaz, María author Berradre-Sáenz, Belén author Villegas-Moreno, María Teresa author Limia, Aurora author Diaz Franco, Asuncion author Monge Corella, Susana author Spanish MPOX vaccine effectiveness study group author Jarrin Vera, Inmaculada author 2024 Background: With over 7,500 cases notified since April 2022, Spain has experienced the highest incidence of mpox in Europe. From July 12th onwards, the Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for individuals at high-risk of mpox, including those receiving pre-exposure prophylaxis for HIV (HIV-PrEP). Our aim was to assess the effectiveness of one dose of MVA-BN vaccine as pre-exposure against mpox virus (MPXV) infection in persons on HIV-PrEP. Methods: We conducted a national retrospective cohort study between July 12 and December 12, 2022. Individuals ≥18 years, receiving HIV-PrEP as of July 12 and with no previous MPXV infection or vaccination were eligible. Each day, we matched individuals receiving a first dose of MVA-BN vaccine and unvaccinated controls of the same age group and region. We used a Kaplan-Meier estimator and calculate risk ratios (RR) and vaccine effectiveness (VE = 1-RR). Results: We included 5,660 matched pairs, with a median follow-up of 62 days (interquartile range 24-97). Mpox cumulative incidence was 5.6 per 1,000 (25 cases) in unvaccinated and 3.5 per 1,000 (18 cases) in vaccinated. No effect was found during days 0-6 post-vaccination (VE -38.3; 95% confidence interval (95%CI): -332.7; 46.4), but VE was 65% in ≥7 days (95%CI 22.9; 88.0) and 79% in ≥14 days (95%CI 33.3; 100.0) post-vaccination. Conclusions: One dose of MVA-BN vaccine offered protection against mpox in a most-at-risk population shortly after the vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time. Clin Infect Dis. 2024 Feb 17;78(2):476-483. 10.1093/cid/ciad645 1537-6591 1058-4838 Clinical Infectious Diseases 37864849 http://hdl.handle.net/20.500.12105/16837 mpox Monkeypox Vaccine effectiveness MVA-BN vaccine Pre-exposure prophylaxis Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study